ARTICLE | Clinical News
Avelumab: Phase III started
April 11, 2016 7:00 AM UTC
Merck and Pfizer began the open-label, international Phase III JAVELIN Renal 101 trial to compare 10 mg/kg IV avelumab every 2 weeks plus twice-daily oral Inlyta axitinib vs. oral Sutent sunitinib a...